Archive for December, 2008
People with a sleep disorder that causes them to kick or cry out during their sleep may be at greater risk of developing dementia or Parkinson’s disease, according to a study published in the December 24, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology. The sleep disorder is called REM sleep behavior disorder.
More: continued here
A slow, chronic starvation of the brain as we age appears to be one of the major triggers of a biochemical process that causes some forms of Alzheimer’s disease.
More: continued here
Researchers have found that two proteins which work in tandem in the brain’s blood vessels present a double whammy in Alzheimer’s disease. Not only do the proteins lessen blood flow in the brain, but they also reduce the rate at which the brain is able to remove amyloid beta, the protein that builds up in toxic quantities in the brains of patients with the disease. The work, described in a paper published online Dec.
More: continued here
New Alzheimer’s Society research will investigate whether curcumin, found in the popular Indian spice turmeric, and a number of drugs for other conditions, could benefit people with Alzheimer’s Researchers at Southampton University will examine whether the drugs could counteract some of the brain changes that are characteristic of the disease.
More: continued here
New public health campaigns will help people understand government guidelines around healthy eating, exercise and drinking alcohol, Public Health Minister Dawn Primarolo outlined today. Responding to figures released today by the NHS Information Centre, the Department of Health highlighted that ongoing and future campaigns would help people to live more healthily. Health awareness campaigns are a vital step towards helping people reduce their risk of dementia.
More: continued here
Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced positive results from its Phase 1 program for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor being developed in collaboration with Roche for cognitive disorders such as Alzheimer’s disease. The Phase 1 program enrolled over 130 subjects and included a single-ascending dose study, a food interaction study, a study in elderly volunteers and a multiple ascending dose study.
More: continued here
MRI scans that detect shrinkage in specific regions of the mid-brain attacked by Alzheimer’s disease accurately diagnose the neurodegenerative disease, even before symptoms interfere with daily function, a study by the Florida Alzheimer’s Disease Research Center (ADRC) in Miami and Tampa found.
More: continued here
Barbara Stephens, Chief Executive of for dementia, the charity responsible for Admiral Nurses says: “Dementia is a complex condition with many and varied causes. There needs to be a comprehensive and co-ordinated response to address this major public health issue.
More: continued here
Anavex Life Sciences Corp. (”ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper published in the current edition of Neuropsychopharmacology. Currently in the late pre-clinical stage, ANAVEX 1-41 is one of the company’s lead compounds for Alzheimer’s disease (AD).
More: continued here
The Council of European Health Ministers adopted far-reaching conclusions on public health strategies to combat neurodegenerative diseases associated with ageing and in particular Alzheimer’s disease on 16 December 2008.
More: continued here





